The Cardiolite cardiac imaging kit will play a major part in the first multicenter study to detect silent ischemia among patients with diabetes, according to DuPont Pharmaceuticals, its manufacturer.
Cardiolite, a technetium-based radiotracer, will be used to screen diabetic patients who have no apparent symptoms, such as chest pain, yet are still at high risk for heart disease. Use of Cardiolite in a nuclear medicine scan non-invasively evaluates the heart’s pumping ability and gauges blood perfusion.
Yale University in New Haven, CT, which will serve as the lead investigation site for the Detection of Ischemia in Asymptomatic Diabetics (DIAD) trial, received a $2 million research grant from the branch of DuPont based in North Billerica, MA. Other investigation sites include Tulane University in New Orleans, the University of Chicago and the University of Virginia in Charlottesville.
By AuntMinnie.com staff writers
August 22, 2000
Related Reading
Heart-disease management, March 15, 2000
Copyright © 2000 AuntMinnie.com
